Drug Target Review

SEPTEMBER 19, 2024

Based on Nobel Prize-winning research, IRLAB has grown rapidly to become recognised and respected as a world-leader in understanding the complex neuropharmacology of CNS disorders, especially Parkinson’s disease (PD). The treatment often initially provides good symptom relief and those affected by the disease can live a largely normal life.

Disease 52

Disease Drugs Treatment Drug Development 52

The Pharma Data

JANUARY 26, 2021

27, 2021 /PRNewswire/ — BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the European Patent Office (EPO) has issued a decision to grant European patent EP 2 448 968 B1 for novel antibodies that could be developed into a treatment for Alzheimer’s disease. and are linked to the company’s project AD1503.

Disease 40

Disease Pharmaceutical Companies Treatment Licensing 40

The Pharma Data

JANUARY 5, 2021

RAD011 is a pivotal-trial ready synthetic cannabidiol oral solution with potential utilization in multiple endocrine and metabolic orphan diseases. We intend to use PWS as the anchor indication and will further investigate additional orphan disease opportunities in due course.”. Disease Highlights.

Disease 52

Disease FDA Approval Clinical Trials Trials 52

The Pharma Data

NOVEMBER 30, 2020

1, 2020 /PRNewswire/ — Sosei Group Corporation (“the Company”) (TSE: 4565) announces it has entered into a global collaboration and license agreement with Biohaven Pharmaceutical Holding Company Ltd. (“Biohaven”, NYSE: BHVN). . TOKYO and CAMBRIDGE, England , Dec.

Small Molecule 40

Small Molecule Licensing Licensing Treatment 40

The Pharma Data

DECEMBER 29, 2020

(NYSE American:PLX) (TASE:PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx ® plant cell-based protein expression system, and Chiesi Global Rare Diseases , a business unit of Chiesi Farmaceutici S.p.A.,

Clinical Trials 52

Clinical Trials Disease Treatment Trials 52

Crown Bioscience

MAY 4, 2021

used in a way that is not described in the license), and only three drugs have been approved exclusively for use in children. Pediatric cancer has been a low priority for pharmaceutical companies due to a combination of factors, including scientific hurdles, additional regulatory burdens, and financial disincentives.

Research 52

Research Pharmaceutical Companies Licensing Licensing 52

Drug Target Review

FEBRUARY 1, 2024

What challenges has the industry faced in developing and commercialising treatments for neurological diseases, including rare diseases? There are a lot of drug development challenges that are, in some cases, unique to neuroscience, including neurological diseases, psychiatric disorders, and rare diseases affecting the nervous system.

Therapies 104

Therapies Drug Development Disease Clinical Development 104

The Pharma Data

NOVEMBER 25, 2020

CAN10 has been designed to block the signalling of the inflammatory cytokines IL-1, IL-33 and IL-36 resulting in unique properties for treatment of inflammatory diseases. The Company’s validated, proprietary F.I.R.S.T 556791-6019, is a biotechnology company that develops antibody-based treatments for life-threatening diseases.

Clinical Trials 52

Clinical Trials Licensing Licensing International 52

Policy Prescription

MAY 28, 2021

NeedyMeds , a non-profit organization known for providing patients with help in finding pharmaceutical company-sponsored prescription assistance programs and other drug savings options, hosted a webinar about drug importation last year called “ Drug Importation: The topic everyone’s talking about.” Emphasis added).

Pharmacy 52

Pharmacy Licensing Licensing Online Pharmacies 52

The Pharma Data

MARCH 16, 2021

Head of Department CNS Diseases Research at Boehringer Ingelheim. “By While peripherally acting COMT inhibitors are currently used as an adjunctive therapy in the treatment of neurological conditions, including Parkinson’s disease, this new collaboration is investigating centrally acting COMT inhibitors in neuropsychiatric disorders.

Licensing 52

Licensing Licensing Research Laboratories Treatment 52

The Pharma Data

OCTOBER 20, 2020

21, 2020 (GLOBE NEWSWIRE) — TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage, specialty pharmaceutical company developing novel nanomedicines to target areas of unmet medical need, today announced the appointment of Thomas H. TLC is consistently ranked top 5% among all listed companies in Taiwan’s Corporate Governance Evaluations.

Licensing 40

Licensing Licensing Pharmaceutical Companies Clinical Trials 40

The Pharma Data

JANUARY 17, 2021

A next generation polymyxin with improved safety and tolerability would be a true breakthrough for treating these difficult infections,” said Sunny Xu Zhu , Chief Medical Officer for Infectious Disease at Everest Medicines. SHANGHAI , Jan. ” About SPR206.

Clinical Trials 52

Clinical Trials Clinical Development Pharmacokinetics Pharmaceutical Companies 52

The Pharma Data

JANUARY 4, 2021

5, 2021 /PRNewswire/ — Sosei Group Corporation (“the Company”) (TSE: 4565) announces it is to regain the worldwide rights to its muscarinic agonist programs. The program was licensed to Allergan in April 2016 , and Allergan was acquired by AbbVie in May 2020. ” About the License Agreement.

Licensing 40

Licensing Licensing Clinical Trials Disease 40

Drug Target Review

OCTOBER 14, 2024

Wilkie’s background as a biochemist and his time at Merck, a leading pharmaceutical company, shaped his early understanding of drug development and business strategy. Neil is a scientific business leader with thirty years’ experience of the pharmaceutical, biotechnology and life sciences investment industries.

Science 52

Science Pharmaceutical Companies Drug Development Pharmaceuticals 52

The Pharma Data

MARCH 2, 2021

Boehringer Ingelheim and Gubra today announced a new research and licensing agreement focused on the identification and validation of targets and innovative peptide compounds for the treatment of obesity. Senior Vice President and Global Head of Cardiometabolic Diseases Research, Boehringer Ingelheim. population will have obesity.

Treatment 52

Treatment Bioinformatics Clinical Development Therapies 52

The Pharma Data

JANUARY 3, 2021

03, 2021 (GLOBE NEWSWIRE) — EyePoint Pharmaceuticals, Inc. NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing innovative ophthalmic products, today announced that Ocumension Therapeutics, a China-based ophthalmic pharmaceutical company traded on the Stock Exchange of Hong Kong (1477.HK),

Pharmaceuticals 52

Pharmaceuticals Pharmaceutical Companies Licensing Licensing 52

The Pharma Data

AUGUST 21, 2020

As an expert in infectious diseases, Jennifer Leeds could see the storm brewing. Fortunately, as a member of the Novartis Business Development & Licensing (BD&L) department, she was in a position to try to help. Jennifer Leeds , Head of West Coast Search and Evaluation, NIBR Business Development & Licensing.

Virus 52

Virus Small Molecule Licensing Licensing 52

The Pharma Data

NOVEMBER 10, 2020

The poster presentation, given by Johan Sandin , CSO at AlzeCure, presents how the mechanisms in the research platform Alzstatin work and shows that the target mechanism within the platform is suitable as a new treatment for Alzheimer’s disease. STOCKHOLM , Nov. STOCKHOLM , Nov. in the brain.

Pharmaceutical Companies 40

Pharmaceutical Companies Disease Treatment Pharmaceuticals 40

Molecule Blog

JANUARY 9, 2023

IP-NFTs upgrade our legacy intellectual system by unifying IP (patents, legal), underlying data (through decentralized storage and access control), and economics (royalties, license fees, sales) into one programmable, transactable, digital unit. ‍ Researchers make proposals to the system for projects that contribute to solving the disease.

Research 52

Research Licensing Licensing Science 52

The Pharma Data

DECEMBER 8, 2020

Some of the funds will be used for the development of therapeutics for oncology and other serious diseases through its proprietary ImmunoTAC technology platform. The ImmunoTAC platform pairs proprietary payloads that modulate key disease modifying pathways with monoclonal antibodies directed at specific disease sites.

RNA 52

RNA Therapies Disease Protein Expression 52

The Pharma Data

OCTOBER 6, 2021

licensed the compound series in 2015, and is continuing to advance the compound into clinical development. Janssen’s work against dengue is just one part of a larger commitment to address the burden of NTDs, a group of about 20 communicable diseases that cause debilitating conditions and affect more than 1.7 Janssen Pharmaceutica, N.V.

Virus 52

Virus Clinical Development Science Disease 52

The Pharma Data

MARCH 2, 2021

Johnson & Johnson (NYSE: JNJ) (the Company) today announced that the U.S. The Company’s single-shot COVID-19 vaccine received EUA from the FDA on February 27, 2021. The Company plans to file for a Biologics License Application (BLA) with the FDA later in 2021. The study enrolled a total of 43,783 participants.

Vaccine 52

Vaccine Clinical Trials FDA Licensing 52

NIH Director's Blog: Drug Development

FEBRUARY 27, 2018

Credit: National Institute of Allergy and Infectious Diseases, NIH A major part of NIH’s mission is to support basic research that generates fundamental knowledge about the nature and behavior of living systems. Previous attempts to quantify the contribution of federal funding to new drug development had looked primarily at patents.

Research 52

Research Science FDA Pharmaceutical Companies 52

The Pharma Data

JANUARY 10, 2021

LA ROCHELLE, France–( BUSINESS WIRE )– Regulatory News: VALBIOTIS (FR0013254851 – ALVAL / eligible for the PEA/SME) (Paris:ALVAL), a French Research & Development company committed to scientific innovation for preventing and combating metabolic diseases, announces its participation in the prestigious ‘J.P.

International 40

International Pharmaceutical Companies Disease Licensing 40

The Pharma Data

NOVEMBER 5, 2020

The Janssen Pharmaceutical Companies of Johnson & Johnson announced two Phase III trials, DISCOVER-1 and 2 demonstrated Tremfya (guselkumab) improved fatigue in adults with active psoriatic arthritis (PsA). There was a handful of positive clinical trial news reported today. Here’s a look. Janssen’s Tremfya.

Clinical Trials 40

Clinical Trials Trials Hospitals Pharmaceutical Companies 40

The Pharma Data

JANUARY 25, 2021

At their option, the collaboration with the European affiliate of a global pharmaceutical company has expanded to three active pharmaceutical ingredients (“API”s). The Company has developed three in-house technology platforms, each with its own unique mechanism to improve delivery of medications to sites of disease.

Licensing 52

Licensing Licensing Production Regulations 52

The Pharma Data

DECEMBER 17, 2020

George Yeh, President of TLC, commenced the conference and welcomed the company’s new Chief Business Officer, Mr. Tom Bliss. With experiences attained in licensing and business development functions from Amgen, Baxter and Johnson & Johnson, Mr. Bliss introduced himself in Mandarin Chinese. SOUTH SAN FRANCISCO, Calif.

Clinical Trials 40

Clinical Trials Trials Pharmaceutical Companies Clinical Pharmacology 40

The Pharma Data

DECEMBER 27, 2020

28, 2020 /PRNewswire/ — United Therapeutics Corporation (Nasdaq: UTHR) announced today an agreement to acquire a Rare Pediatric Disease Priority Review Voucher (PRV), which it plans to use with a forthcoming New Drug Application (NDA) with the U.S. SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C. , Food and Drug Administration (FDA).

FDA 52

FDA Bioinformatics Disease Production 52

Practical Cheminformatics

DECEMBER 7, 2023

In these cases, broadening your skillset into other areas like medicinal chemistry, pharmacology, biophysics, pharmacokinetics, and disease biology is important. It should be noted that not all biotechs skimp on software licenses. Some computational chemists may aspire to eventually lead drug discovery projects or teams.

Computational Chemistry 86

Computational Chemistry Pharmacokinetics Drugs Pharmaceutical Companies 86

The Pharma Data

OCTOBER 14, 2020

In carrying out the activities contemplated under the R&D Agreement, the companies have evaluated detailed specifications for implantable medical devices focused on multiple diseases with high unmet medical needs. is a pharmaceutical company conducting business in more than 70 countries around the world.

Disease 40

Disease Production Pharmaceuticals Clinical Trials 40

The Pharma Data

NOVEMBER 22, 2020

MP0420 is subject to an option and license agreement with Novartis AG to develop, manufacture and commercialize Molecular Partners’ anti-COVID-19 DARPin® program. www.molecularpartners.com ; Follow the Company on Twitter at @MolecularPrtnrs. Chief Medical Officer of Molecular Partners.

Trials 40

Trials Clinical Trials Licensing Licensing 40

The Pharma Data

JANUARY 24, 2021

and a disease control rate (DCR) of 86.2% About Fast Track Designation (FTD) The FTD aims to facilitate the development and accelerate the review process of treatments for serious or life-threatening diseases or conditions that remain unmet clinical needs. for advanced mucosal melanoma with a manageable safety profile.

FDA 40

FDA Clinical Trials Trials Treatment 40

Advarra

JULY 19, 2022

The sponsor is the pharmaceutical company conducting the trial. A: Working in a pharmaceutical company is the best way to learn this. Each company will have its own processes, but they will all have the same result. If you get approval, then you can conduct clinical trials for other disease indications.

Packaging 52

Packaging FDA Trials Regulations 52

The Pharma Data

AUGUST 19, 2021

The Janssen Pharmaceutical Companies of Johnson & Johnson today announced preliminary data from the Phase 1 CHRYSALIS study evaluating RYBREVANT TM (amivantamab-vmjw) for the treatment of patients with non-small cell lung cancer (NSCLC) with mesenchymal-epithelial transition (MET) exon 14 skipping (METex14) mutations.

Treatment 52

Treatment FDA Approval Pharmacokinetics FDA 52

Molecule Blog

MARCH 17, 2023

Early-stage therapeutic research generally involves target-based or phenotypic screening using cell lines (in vitro) and model organisms (in vivo), depending on the disease model being studied. Funding typically comes from a mix of government agencies, venture capitalists (VCs), and pharmaceutical companies.

Engineering 52

Engineering Research Clinical Trials Government 52

The Pharma Data

OCTOBER 27, 2020

Impairment of investment in privately-held company (2). Unrealized gain on investment in privately-held company (3). License-related fees (5). License-related fees (5). 2020.

FDA 40

FDA Production Licensing Licensing 40

The Pharma Data

NOVEMBER 15, 2020

a publicly traded biopharmaceutical company, from 2012 to December 2019, managing its international, legal, quality, intellectual property and compliance functions, after serving in other executive roles at Acorda starting in 2004. Before joining Acorda, Ms. About Athersys.

Clinical Trials 40

Clinical Trials Trials Production Therapies 40